[The effect of 6-alpha-fluoro-16-alpha-methyl-1-dehydro-corticosterone (fluocortolone) in internal diseases].
D000208:Acute Disease; D000309:Adrenal Insufficiency / Q000188:drug therapy; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001249:Asthma / Q000188:drug therapy; D001991:Bronchitis / Q000188:drug therapy; D002908:Chronic Disease; D003093:Colitis, Ulcerative / Q000188:drug therapy; D003109:Colonic Diseases, Functional / Q000188:drug therapy; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use*; D006402:Hematologic Diseases / Q000188:drug therapy; D006801:Humans; D007388:Internal Medicine; D007938:Leukemia / Q000188:drug therapy; D008107:Liver Diseases / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D012216:Rheumatic Diseases / Q000188:drug therapy; D012213:Rheumatic Fever / Q000188:drug therapy; D012859:Sjogren's Syndrome / Q000188:drug therapy; D013167:Spondylitis, Ankylosing / Q000188:drug therapy
D005938:Glucocorticoids; D011239:Prednisolone
Die Wirkung des 6-alpha-Fluor-16-alpha-methyl-1-dehydro-corticosterons (Fluocortolon) bei internen Erkrankungen.